Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-166695
Filing Date
2026-04-21
Accepted
2026-04-21 16:00:16
Documents
20
Period of Report
2026-04-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A trvi-20260421.htm   iXBRL DEF 14A 1340704
2 GRAPHIC img92490068_0.jpg GRAPHIC 55345
3 GRAPHIC img92490068_1.jpg GRAPHIC 20442
4 GRAPHIC img92490068_2.jpg GRAPHIC 55345
5 GRAPHIC img92490068_3.gif GRAPHIC 197028
6 GRAPHIC img92490068_4.gif GRAPHIC 190645
7 GRAPHIC img92490068_5.jpg GRAPHIC 20442
8 GRAPHIC img92490068_6.jpg GRAPHIC 699706
9 GRAPHIC img92490068_7.jpg GRAPHIC 187083
  Complete submission text file 0001193125-26-166695.txt   5751636

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20260421.xsd EX-101.SCH 8359
23 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20260421_htm.xml XML 366875
Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38886 | Film No.: 26879238
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)